BP

433.15

-0.68%↓

BP

433.15

-0.68%↓

BP

433.15

-0.68%↓

BP

433.15

-0.68%↓

BP

433.15

-0.68%↓

Search

Smith & Nephew PLC

Uždarymo kaina

1,081.5 -0.14

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1071

Max

1094.5

Pagrindiniai rodikliai

By Trading Economics

Pajamos

107M

Pardavimai

1.4B

P/E

Sektoriaus vid.

30

28.777

Pelnas, tenkantis vienai akcijai

0.376

Dividendų pajamingumas

2.71

Pelno marža

7.57

Darbuotojai

17,349

EBITDA

260M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+15.09% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

2.71%

5.16%

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

520M

9.5B

Ankstesnė atidarymo kaina

1081.64

Ankstesnė uždarymo kaina

1081.5

Smith & Nephew PLC Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-03-31 22:45; UTC

Svarbiausios naujienos

Intel's New CEO Plots Turnaround; 'We Need to Improve'

2025-03-31 23:54; UTC

Rinkos pokalbiai

Nikkei May Rise After Monday's Selloff -- Market Talk

2025-03-31 23:44; UTC

Rinkos pokalbiai

Gold Edges Higher Amid Prospects of Broader, Higher U.S. Tariffs -- Market Talk

2025-03-31 23:15; UTC

Rinkos pokalbiai

Tower Shares Ease After Bain Capital Exit -- Market Talk

2025-03-31 23:15; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-03-31 22:33; UTC

Svarbiausios naujienos

Trump Administration Targets Harvard With Review of $9 Billion in Federal Funding -- Update

2025-03-31 22:28; UTC

Uždarbis

China Vanke: Weak China Real-Estate Market Weighed on Results >000002.SZ

2025-03-31 22:28; UTC

Uždarbis

China Vanke 2024 Loss CNY49.48B Vs. Net CNY12.16B >000002.SZ

2025-03-31 22:28; UTC

Uždarbis

China Vanke 2024 Rev CNY343.18B Vs. CNY465.74B >000002.SZ

2025-03-31 22:28; UTC

Uždarbis

China Vanke Swings to Loss for 2024 >000002.SZ

2025-03-31 21:47; UTC

Svarbiausios naujienos

Intel's New CEO Says Turnaround 'Won't Be Easy' -- Barrons.com

2025-03-31 21:44; UTC

Svarbiausios naujienos

Trump Administration Targets Harvard With Review of $9 Billion in Federal Funding -- WSJ

2025-03-31 21:21; UTC

Rinkos pokalbiai

Intel Has 'A Lot of Hard Work Ahead' in Turnaround, CEO Says -- Market Talk

2025-03-31 21:18; UTC

Svarbiausios naujienos

Copper Is 2025's Hottest Commodity -- Update

2025-03-31 21:09; UTC

Svarbiausios naujienos

Senate Aims to Advance Trump Tax Agenda While Postponing Spending-Cut Fight -- Update

2025-03-31 21:02; UTC

Uždarbis

Freeport-McMoRan Sees 1Q Gold Sales 100,000 Ounces Below Previous Guidance of 225,000 Ounces >FCX

2025-03-31 21:01; UTC

Uždarbis

Freeport-McMoRan Backs 1Q Consolidated Copper Sales of 850M Pounds >FCX

2025-03-31 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2025-03-31 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-03-31 20:37; UTC

Svarbiausios naujienos

A Wild Quarter for U.S. Stocks Sends Investors Abroad -- 3rd Update

2025-03-31 20:17; UTC

Svarbiausios naujienos

Dow Bounced Back After Tariff Concerns Hit Global Markets -- WSJ

2025-03-31 20:13; UTC

Svarbiausios naujienos

A Wild Quarter for U.S. Stocks Sends Investors Abroad -- 2nd Update

2025-03-31 20:03; UTC

Svarbiausios naujienos

A Wild Quarter for U.S. Stocks Sends Investors Abroad -- Update

2025-03-31 19:09; UTC

Rinkos pokalbiai

Oil At 5-Week High as Trump Makes More Sanction Threats -- Market Talk

2025-03-31 18:56; UTC

Rinkos pokalbiai

U.S. Natural Gas Gains With Help From Weather -- Market Talk

2025-03-31 18:54; UTC

Rinkos pokalbiai

Canadian Banks' Fundamentals to Support Credit Ratings Near Term -- Market Talk

2025-03-31 18:40; UTC

Rinkos pokalbiai

Walmart's Low Income Consumer Appears Increasingly Strained -- Market Talk

2025-03-31 18:34; UTC

Rinkos pokalbiai

Ball, Crown Won't Be Materially Hurt if Soda Kicked Off Food Stamps -- Market Talk

2025-03-31 18:28; UTC

Rinkos pokalbiai

Gold Climbs to Close Out Quarter -- Market Talk

2025-03-31 18:03; UTC

Svarbiausios naujienos

Dow Edges Higher, Tariff Concerns Drag Down Global Markets -- WSJ

Akcijų palyginimas

Kainos pokytis

Smith & Nephew PLC Prognozė

Kainos tikslas

By TipRanks

15.09% į viršų

12 mėnesių prognozė

Vidutinis 1,248.7 GBX  15.09%

Aukščiausias 1,400 GBX

Žemiausias 1,025 GBX

Remiantis 10 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Smith & Nephew PLC kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

10 ratings

5

Pirkti

5

Laikyti

0

Parduoti

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

EBITDA

Veiklos pelnas

$

Apie bendrovę Smith & Nephew PLC

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.